Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pyrilamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.90 |
| ▸ | LMNA | P02545 | 5/20 | 0.90 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.90 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.90 |
| ▸ | DRD1 | P21728 | 4/20 | 0.90 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.90 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.90 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.90 |
| ▸ | HTR2A | P28223 | 3/20 | 0.90 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.90 |
| ▸ | TSHR | P16473 | 3/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.90 |
| ▸ | HTR2C | P28335 | 2/20 | 0.90 |
| ▸ | HTR2B | P41595 | 2/20 | 0.90 |
| ▸ | MEN1 | O00255 | 2/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrilamine SCHEMBL622845 | 0.97 | LMNA (0.95) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL28086659 | 0.97 | LMNA (0.95) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL19114 | 0.95 | LMNA (1.00) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL29444024 | 0.95 | LMNA (1.00) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL28350675 | 0.94 | LMNA (0.97) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL22118219 | 0.94 | LMNA (0.97) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL28823277 | 0.94 | LMNA (0.97) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL4891045 | 0.94 | LMNA (0.97) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Thonzylamine SCHEMBL121996 | 0.88 | LMNA (0.97) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL4450392 | 0.88 | CHRM2 (0.86) | LMNACHRM2ADRA2ADRD1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742707-A4 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1742707-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | Hypnion, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005103041-A9 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005103041-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION, INC. (US) | 2005-11-03 | — | — | WO | disclosed |